In Brief: Sanofi/QLT Phototherapeutics
Executive Summary
Sanofi/QLT Phototherapeutics: Photofrin (porfimer sodium) photodynamic therapy supplemental NDA submitted Feb. 10 for reduction of obstruction and palliation of symptoms in patients with obstructing endobronchial non-small cell lung cancer, and for treatment of endobronchial carcinoma in situ or microinvasive NSCLC in patients for whom surgery and radiotherapy are not indicated. Photofrin is approved for palliative treatment of esophageal cancer...